BridgeBio Oncology Therapeutics, Inc. develops clinical-stage oncology therapeutics focused on RAS-pathway malignancies and cancers driven by RAS and PI3Kα biology. Company news centers on small-molecule pipeline updates, including BBO-11818, a selective oral pan-KRAS inhibitor, and BBO-10203, a RAS:PI3Kα breaker designed to disrupt oncogenic signaling.
Recurring updates include preclinical and clinical data presentations, oncology conference disclosures, FDA regulatory designations, publication of research data, inducement equity grants, and governance changes. BBOT also reports operating and financial results tied to development-stage biotechnology activities.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, debuting as a public company on August 11, 2025. The transaction includes a $261 million PIPE investment and approximately $120 million from Helix's trust, resulting in total gross proceeds of $382 million.
The company, focused on RAS-pathway malignancies, will have approximately $490 million in total cash post-transaction. BBOT's pipeline includes three clinical-stage candidates: BBO-8520 for KRASG12C mutant lung cancer, BBO-10203 for various cancer types including breast and colorectal cancer, and BBO-11818 for KRAS mutant solid tumors.
The SPAC merger achieved a notably low redemption rate of 39%, the second-lowest for a biotech de-SPAC since 2022, demonstrating strong investor confidence. Trading will commence on Nasdaq under ticker "BBOT" on August 12, 2025.
[ "Raised substantial capital with $382 million in gross proceeds from SPAC merger and PIPE", "Achieved second-lowest redemption rate (39%) for biotech de-SPAC since 2022, indicating strong investor confidence", "Strong cash position of $490 million post-transaction", "Backing from premier institutional investors including Cormorant, Deerfield, Wellington Management", "Three clinical-stage drug candidates targeting major cancer pathways" ]